Antitumor effects and mechanisms of CpG ODN combined with attenuated Salmonella-delivered siRNAs against PD-1

Jia, Xiaolong; Guo, Jing; Guo, Sheng; Zhao, Tiesuo; Liu, Xiaoming; Cheng, Chenchen; Wang, Lei; Zhang, Beibei; Meng, Chenchen; Jia, Hui‐Zhen; Luo, Enjie

doi:10.1016/j.intimp.2020.107052

Cited by 13 publications

(6 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In melanoma therapy, recombinant S. typhimurium transfected with the interferon-gamma gene plasmid integrated into the N-terminal region (residues 1–160) of a surface immunogenic protein demonstrated obvious toxicity to cancer cells ( Yoon et al, 2017 ). In addition, S. typhimurium loaded with CpG ODN and PD-1-siRNA induced innate immunity and inhibited PD-1 expression, thus killing cancer cells ( Jia et al, 2021 ).…”

Section: Geb In Disease Managementmentioning

confidence: 99%

Genetically engineered bacterium: Principles, practices, and prospects

et al. 2022

View full text Add to dashboard Cite

Advances in synthetic biology and the clinical application of bacteriotherapy enable the use of genetically engineered bacteria (GEB) to combat various diseases. GEB act as a small ‘machine factory’ in the intestine or other tissues to continuously produce heterologous proteins or molecular compounds and, thus, diagnose or cure disease or work as an adjuvant reagent for disease treatment by regulating the immune system. Although the achievements of GEBs in the treatment or adjuvant therapy of diseases are promising, the practical implementation of this new therapeutic modality remains a grand challenge, especially at the initial stage. In this review, we introduce the development of GEBs and their advantages in disease management, summarize the latest research advances in microbial genetic techniques, and discuss their administration routes, performance indicators and the limitations of GEBs used as platforms for disease management. We also present several examples of GEB applications in the treatment of cancers and metabolic diseases and further highlight their great potential for clinical application in the near future.

show abstract

Section: Geb In Disease Managementmentioning

confidence: 99%

Genetically engineered bacterium: Principles, practices, and prospects

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Small-interfering ribonucleic acids (siRNA) are other co-delivery substances for enhanced TLR agonist delivery [ 91 ]. In a melanoma cell (B16)-injected C57BL/6 mouse model, a delivery of artificially combined siRNA targeting programmed cell death protein 1(PD-1-siRNA) and cytosine-phosphate-guanine oligodeoxynucleoties (CpG ODN) effectively reduced tumor size, and exhibited the longest survival, as compared with any single delivery of either siRNA or CpG ODN TLR agonist.…”

Section: Combinative Delivery Of Tlr Agonists With Various Biochemical Co-factors Inducing Immune Systemmentioning

confidence: 99%

Engineering Therapeutic Strategies in Cancer Immunotherapy via Exogenous Delivery of Toll-like Receptor Agonists

2021

View full text Add to dashboard Cite

As a currently spotlighted method for cancer treatment, cancer immunotherapy has made a lot of progress in recent years. Among tremendous cancer immunotherapy boosters available nowadays, Toll-like receptor (TLR) agonists were specifically selected, because of their effective activation of innate and adaptive immune cells, such as dendritic cells (DCs), T cells, and macrophages. TLR agonists can activate signaling pathways of DCs to express CD80 and CD86 molecules, and secrete various cytokines and chemokines. The maturation of DCs stimulates naïve T cells to differentiate into functional cells, and induces B cell activation. Although TLR agonists have anti-tumor ability by activating the immune system of the host, their drawbacks, which include poor efficiency and remarkably short retention time in the body, must be overcome. In this review, we classify and summarize the recently reported delivery strategies using (1) exogenous TLR agonists to maintain the biological and physiological signaling activities of cargo agonists, (2) usage of multiple TLR agonists for synergistic immune responses, and (3) co-delivery using the combination with other immunomodulators or stimulants. In contrast to naked TLR agonists, these exogenous TLR delivery strategies successfully facilitated immune responses and subsequently mediated anti-tumor efficacy.

show abstract

“…Unmethylated cytosine-phosphate-guanine oligodeoxynucleotides (CpG) as an immune activator have attracted more and more attention due to their excellent effect in tumor immunotherapy. [17][18][19] After being internalized by immune cells, such as dendritic cells (DCs), CpG can activate these immune cells through specific interaction with Toll-like receptor 9 (TLR9) in the lysosomes, and further activate natural killer cells and cytotoxic T lymphocytes to kill tumor cells. 20 Chen et al 21 designed an Au DENPs/ CpG complex, which can induce the maturation of DCs in vitro and further activate T cells.…”

Section: Introductionmentioning

confidence: 99%

⁶⁸Ga-labeled dendrimer-entrapped gold nanoparticles for PET/CT dual-modality imaging and immunotherapy of tumors

Zhao

Liang

et al. 2022

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

Antitumor effects and mechanisms of CpG ODN combined with attenuated Salmonella-delivered siRNAs against PD-1

Cited by 13 publications

References 31 publications

Genetically engineered bacterium: Principles, practices, and prospects

Genetically engineered bacterium: Principles, practices, and prospects

Engineering Therapeutic Strategies in Cancer Immunotherapy via Exogenous Delivery of Toll-like Receptor Agonists

⁶⁸Ga-labeled dendrimer-entrapped gold nanoparticles for PET/CT dual-modality imaging and immunotherapy of tumors

Contact Info

Product

Resources

About

Antitumor effects and mechanisms of CpG ODN combined with attenuated Salmonella-delivered siRNAs against PD-1

Cited by 13 publications

References 31 publications

Genetically engineered bacterium: Principles, practices, and prospects

Genetically engineered bacterium: Principles, practices, and prospects

Engineering Therapeutic Strategies in Cancer Immunotherapy via Exogenous Delivery of Toll-like Receptor Agonists

68Ga-labeled dendrimer-entrapped gold nanoparticles for PET/CT dual-modality imaging and immunotherapy of tumors

Contact Info

Product

Resources

About

⁶⁸Ga-labeled dendrimer-entrapped gold nanoparticles for PET/CT dual-modality imaging and immunotherapy of tumors